Introduction
In this review we discuss the gut-driven pathophysiologic pathways involved in gut dysfunction and symptom generation in irritable bowel syndrome (IBS), including immune activation, dysmotility, altered mucosal barrier function, and visceral perception. This allows us to logically review the possible targets of probiotic therapy in IBS. Finally, we evaluate the relevant clinical trials published to date on probiotics and IBS.
Gut dysfunction in irritable bowel syndrome
The current goal of treatment in IBS is to alleviate symptoms and improve quality of life. The gut-driven pathophysiologic mechanisms believed to be involved in the origin or maintenance of IBS symptoms include intestinal infection and immune activation, dysmotility, abnormal fermentation, and visceral hypersensitivity [1-4,5 • ,6-10]. Therapeutic approaches targeting some of these mechanisms have been developed and used with varied clinical efficacy [11] .
Increased intestinal permeability and abnormal central processing of peripheral stimuli have also been proposed as possible mechanisms leading to or exacerbating IBS symptoms [12] . Changes in gut permeability have been demonstrated in postinfective IBS (PI-IBS), but this has not been proved in the unselected IBS population [2] .
It is the opinion of the authors that low-grade inflammation is the basis for gut dysfunction in a proportion of patients with IBS. A recent study has shown that Bifidobacterium infantis 35634 improved systemic cytokine abnormalities and normalized symptoms in IBS patients [13 •• ]. This raises the possibility that specific probiotics may modify the natural history of IBS.
Immune activation in irritable bowel syndrome
Infectious gastroenteritis is the most significant environmental risk factor identified to date for the development of IBS [1] . IBS symptoms have been reported to develop in a significant proportion of individuals with documented Campylobacter, Salmonella, Escherichia coli, and Shigella infection as well as viral infection [2, [14] [15] [16] . Evidence of immune activation is not restricted to patients with PI-IBS, and it has also been reported in a proportion of unselected IBS patients with no history of gastroenteritis [2-4,5 • ,17].
There is evidence for an imbalance in the genetic regulation of counterinflammatory cytokine secretion in patients with IBS [18] . This may promote a defective downregulation of immune responses to normal inflammatory stimuli in IBS. A recent study by Van Der Veek et al. [19] demonstrated changes in the genetic control of cytokines that play a critical role in regulating inflammation in the gut. The combination of genotypes encoding for high tumor necrosis factor-a secretion, a proinflammatory cytokine, and low interleukin-10 secretion, a counterregulatory cytokine, was significantly more prevalent in IBS patients than in control individuals. Phenotypic evidence demonstrating a lower ration of interleukin-10 to tumor necrosis factor-a in IBS patients has recently confirmed these earlier genotypic studies [13
Putative mechanisms of action of probiotics in irritable bowel syndrome Inflammatory bowel syndrome is heterogeneous both in its clinical presentation and in its pathogenesis. No treatment to date has been proved to be substantially effective, although a recent study by O'Mahony et al. [13 •• ] is encouraging. Probiotics may target one or more pathophysiologic pathways in IBS, and specific probiotics with more than one mechanism of action may prove to be an attractive 'natural' approach compared with conventional drug therapy for patients with IBS. Eventually, combinations of specific strains carefully selected on the basis of documented targets in the gastrointestinal tract may provide the best therapeutic approach.
A recent metaanalysis has shown that probiotic therapy reduces the duration of infectious diarrhea in children [20] . This is particularly relevant to PI-IBS, in which a shorter duration of the initial gastroenteritis episode or prevention of colonization by pathogens may reduce the risk for the subsequent development of IBS [21, 22] .
Numerous studies have demonstrated antiinflammatory effects of probiotics in animal models of inflammatory bowel disease [23, 24] . We have shown in a murine model of PI-IBS that Lactobacillus paracasei NCC2461 attenuates postinfective muscle contractility, in part through modu- Lactobacillus farciminis was shown to enhance barrier function and prevent bacterial translocation in trinitrobenzene sulfonic acid-induced colitis in rats [26] . Others have been unable to detect an improvement in gut permeability after trinitrobenzene sulfonic acid-induced colitis following administration of L. plantarum 299 (LP299). Human studies suggest that L. rhamnosus 19070-2 and L. reuteri DSM 12246 stabilize intestinal barrier function in children with atopic dermatitis [27] . Other studies, however, using a variety of probiotic species in critically ill patients, failed to demonstrate improvement in intestinal permeability despite favorable changes in the systemic inflammatory response and the microbial composition of the gastrointestinal tract [28, 29] . The identification of subgroups of IBS patients in whom barrier dysfunction underlies symptom generation should be a prior logical step to the application of probiotic therapy to target barrier dysfunction.
Dysmotility is considered to underlie altered bowel habit, which is a common symptom in IBS patients. Until recently, the neuromuscular apparatus was not considered as a possible target for probiotic therapy, presumably because of its distance from the lumen. Of five different probiotic species tested, only L. paracasei was able to significantly attenuate muscle dysfunction in the model of Trichinella spiralis-induced IBS. The beneficial effect was observed even when the probiotic was administered long after resolution of the initial infection [25] . L. paracasei significantly improved postinfective dysmotility in vivo, as assessed by video fluoroscopy and image analysis. Oral administration of spent culture medium from L. paracasei, devoid of live bacteria, also improved postinfective dysmotility [30] . Taken together, these studies demonstrate that specific probiotics may target the neuromuscular apparatus and improve muscle function in PI-IBS.
Bloating and abdominal distension is commonly present in patients with IBS. Dysmotility and consequently difficulty in propelling gas may underlie these symptoms. King et al. [31] have shown a greater gas production in IBS patients than in control individuals, which suggests that abnormal fermentation may be responsible for bloating in some IBS patients. Probiotics aimed at reducing abnormal fermentation may be useful only in those patients in whom abnormal fermentation due to altered flora can be documented [32] .
Pain is a cardinal symptom in IBS, and visceral hypersensitivity is believed to underlie this symptom. There is some evidence that specific probiotics may modulate neurotransmission in the gut. The administration of Saccaromyces boulardii to pigs has been shown to modulate the expression of neuronal markers in the submucous plexus [33] . L. farciminis has been shown to attenuate visceral hypersensitivity in rats [26] . We have found that the administration of L. paracasei NCC2461 attenuates the visceral hypersensitivity and sensory neurotransmitter expression associated with antibiotic administration [34] . Taken together, these results raise the possibility that specific probiotics may affect neurotransmission and modulate visceral perception. Considerable research is required in this area, both in animal models of IBS and in IBS patients.
Clinical studies
Several uncontrolled studies have claimed beneficial effects of probiotics in functional bowel disorders. This review is limited to the eight placebo-controlled trials shown in Table 1 [13 • , [35] [36] [37] [38] [39] [40] [41] .
Streptococcus faecium was administered for 4 weeks to patients presenting with functional bowel symptoms for at least 6 months. The physicians' overall assessment after 4 weeks of treatment determined that 81% of patients taking S. faecium reported a beneficial effect, compared with 41% of patients taking placebo [35] .
Other studies have reported improvement in specific symptoms, which suggests a role for altered microbial flora in symptom generation in IBS. L. plantarum DSM 9843, but not placebo, decreased flatulence in patients with IBS; however, pain was reduced in both probiotic-treated and placebo-treated individuals [36] . L. plantarum has been used in other studies, with conflicting results. Sen et al [37] administered L. plantarum 299V or placebo to IBS patients in a crossover fashion. No beneficial effect was observed on colonic fermentation or symptoms after administration of the probiotic. By contrast, Saggioro [38] reported a significant decrease in pain using a either a combination of L. plantarum LP01 with B. breve BR0 or a combination of L. plantarum LP01 with L. acidophilus LA01. Neidzielin et al [39] reported resolution of abdominal pain in patients receiving L. plantarum 299V in comparison with placebo-treated patients.
A study using L. casei strain GG did not find significant improvement in symptoms in patients with IBS; however, a subgroup of patients with diarrhea-predominant symptoms showed a trend toward a decrease in the number of loose stools when treated with this probiotic [40] . Kim et al [41] administered a cocktail of eight probiotic strains (VSL#3) to diarrhea-predominant IBS patients. The only symptom that was significantly reduced in patients randomized to VSL#3 for 8 weeks was abdominal bloating (Table 1) .
A recent study examined the effect of two probiotics, L. salivarius UCC4331 and B. infantis 35624, in patients fulfilling the Rome II criteria for IBS. Patients were randomized to receive either one of the two probiotics or placebo for 8 weeks. Symptoms of IBS were recorded daily and assessed each week. Quality of life assessment, stool microbiologic studies, and blood sampling were performed at the beginning and at the end of treatment. The patients receiving B. infantis had decreased composite symptom scores for every week during treatment and during the 4-week washout period. L. salivarius achieved a significant reduction of the symptom score only during the second week of treatment. Surprisingly, and despite improvement in composite symptom scores, quality of life was not improved in patients treated with probiotics [13] . One finding that distinguishes this study from the previous trials is that patients with IBS showed a reduced basal systemic ratio of interleukin-10 to interleukin-12 and that this was normalized by specific probiotic administration. The reported altered ratio of interleukin-10 to interleukin-12 is consistent with the hypothesis that in a substantial proportion of patients with IBS, gut dysfunction and symptom origin are immune mediated.
All clinical trials performed to date are subject to methodologic caveats, including low numbers of patients and dubious statistical analysis. Moreover, comparison between trials is hampered by the different inclusion criteria, the heterogeneity of IBS patients, the different probiotic preparations, and the treatment protocols used; however, it is the opinion of the authors of this review that although there is not enough evidence to enable clear guidelines to be drawn for the use of any specific probiotic in IBS, larger well-designed clinical studies are warranted. This may prove to be a long way off because extrapolations from results with one probiotic to another, including from the same species but a different strain, seem to be inappropriate.
Conclusion
Considerable research is still needed in the area of probiotics and IBS. Basic research will be useful in identifying potential probiotic strains and gastrointestinal targets.
These strains can be then tested in large well-designed clinical trials. Although extrapolation from animal studies to clinical trials is not always possible, this is the only sensible practical approach that will select potentially useful probiotic strains on a pathophysiologic basis.
Clinical studies will be crucial to elaborate clear guidelines for the use of probiotics in IBS. Larger clinical studies using specific probiotic strains are needed. Ideally, these studies should apply probiotic strains with known therapeutic targets previously determined in animal models and should include symptom and quality of life assessments as well as objective markers of intestinal immune activation and gut function.
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